000 04099nam a22005175i 4500
001 978-94-007-7149-9
003 DE-He213
005 20140220082944.0
007 cr nn 008mamaa
008 130909s2013 ne | s |||| 0|eng d
020 _a9789400771499
_9978-94-007-7149-9
024 7 _a10.1007/978-94-007-7149-9
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aStaibano, Stefania.
_eeditor.
245 1 0 _aProstate Cancer: Shifting from Morphology to Biology
_h[electronic resource] /
_cedited by Stefania Staibano.
264 1 _aDordrecht :
_bSpringer Netherlands :
_bImprint: Springer,
_c2013.
300 _aXVIII, 296 p. 41 illus., 38 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aForeword. Preface. List of contributors. I Clues to morphological diagnosis and prognosis evaluation.-Update on diagnostic criteria, on biopsy and surgical specimen: pre-invasive lesions, from epithelial cell hyperplasia to carcinoma in situ invasive carcinoma. First-line immunophenotyping of prostate diseases -- II Molecular pathology -- Molecular determinants of cancer-related inflammation -- Apoptosis and autophagy -- Androgen receptor and steroidogenesis pathways -- Neuroendocrine differentiation – role of somatostatin receptors (SSTRs) for diagnosis, prognosis, and therapy -- Metastatic dissemination -- Resistance to castration - resistance to drugs -- Crossroads of signaling pathways. III Genetic and Epigenetic Events in prostate cancer -- Gene polymorphisms -- Expression signature -- Mapping prostate cancer aggressiveness loci -- Epigenetic mechanisms: histone acetylation, DNA methylation, miRNA, chromatin modifiers. IV A modern approach to therapy of prostate cancer: targeting the deadly subset.-Molecular markers for patient selection and stratification: personalized prognostic predictive models -- Targeting tumor angiogenesis -- Efficacy of signal transduction inhibition in advanced prostate cancer -- Therapeutic targeting of the bone pre-metastatic niche -- Counteracting hypoxia in radio-resistant metastatic lesions -- “Synthetic lethality”: molecular co-targeting to restore the DNA -- Repair mechanisms in prostate cancer cells concluding remarks. Index.
520 _aThe aim of this book will be to contribute to the education of a new generation of experts in urology, molecular biology, pathology and oncology, offering them sufficient knowledge in basic and translational research to be fluency in the web of interacting networks playing a role in prostate cancer development, progression, metastasis and drug-resistance.The volume will cover the latest innovative researches in prostate cancer, with particular emphasis to the state-of-the-art analysis technologies that are essential for the accurate identification of molecular targets for disease diagnosis, molecular mechanisms of tumorigenesis, markers for susceptibility, molecular-based prognostic prevision, characterization of biomarkers of drug efficacy and drug resistance, validation of new therapeutics and diagnostics. Current advancements on the intersecting data concerning transcriptomes, proteomes, and the molecular techniques referred as "omes”, will be reported and discussed.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aHuman genetics.
650 0 _aGene expression.
650 0 _aDrug interactions.
650 0 _aPathology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aHuman Genetics.
650 2 4 _aGene Expression.
650 2 4 _aDrug Resistance.
650 2 4 _aPathology.
650 2 4 _aOncology.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789400771482
856 4 0 _uhttp://dx.doi.org/10.1007/978-94-007-7149-9
912 _aZDB-2-SBL
999 _c100002
_d100002